These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25399490)

  • 1. Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.
    Liu BL; Liu SJ; Baskys A; Cheng H; Han Y; Xie C; Song H; Li J; Xin XY
    BMC Cancer; 2014 Nov; 14():829. PubMed ID: 25399490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
    Wang Y; Li M; Meng F; Lou G
    Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expressions of CD133, E-cadherin, and Snail in epithelial ovarian cancer and their clinicopathologic and prognostic implications].
    Yu L; Zhou L; Wu S; Song W; Cheng Z; Guo B
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Aug; 35(9):1297-302. PubMed ID: 26403742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
    Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
    Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm.
    Garson K; Vanderhyden BC
    Reproduction; 2015 Feb; 149(2):R59-70. PubMed ID: 25301968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.
    Hu JL; Hu XL; Han Q; Guo AY; Wang CJ; Wen YY; Cang SD
    Gene Ther; 2017 Jul; 24(7):392-398. PubMed ID: 28436941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system metastatic epithelial ovarian cancer. Clinical parameters and prognostic factors: a multicenter study of Anatolian Society of Medical Oncology.
    Seber S; Turkmen E; Harputoğlu H; Yeşil H; Arpacι E; Menekşe S; Pilancι K; Oruç Z; Taskoylu BY; Gumusay O; Aksoy A; Karaagac M; Ozarslan E; Yetisyigit T
    Eur J Gynaecol Oncol; 2017; 38(2):227-231. PubMed ID: 29953785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
    Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
    Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nervous system metastases from epithelial ovarian cancer: prognostic factors and outcomes.
    Cormio G; Loizzi V; Falagario M; Calace A; Colamaria A; De Tommasi A; Selvaggi LE
    Int J Gynecol Cancer; 2011 Jul; 21(5):816-21. PubMed ID: 21613959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
    Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
    Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
    Mariya T; Hirohashi Y; Torigoe T; Asano T; Kuroda T; Yasuda K; Mizuuchi M; Sonoda T; Saito T; Sato N
    Cancer Immunol Res; 2014 Dec; 2(12):1220-9. PubMed ID: 25324403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy.
    Kastritis E; Efstathiou E; Gika D; Bozas G; Koutsoukou V; Papadimitriou C; Pissakas G; Dimopoulos MA; Bamias A
    Int J Gynecol Cancer; 2006; 16(3):994-9. PubMed ID: 16803475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer.
    Wu HH; Wang PH; Yeh JY; Chen YJ; Yen MS; Huang RL; Tsai YJ; Yuan CC
    Taiwan J Obstet Gynecol; 2014 Mar; 53(1):30-4. PubMed ID: 24767643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
    Paek J; Lee M; Nam EJ; Kim SW; Kim YT
    Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.
    Petrillo M; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Vizzielli G; Pedone Anchora L; Nero C; Margariti PA; Scambia G
    Gynecol Oncol; 2013 Oct; 131(1):36-41. PubMed ID: 23791829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer.
    Liang J; Yang B; Cao Q; Wu X
    Gynecol Obstet Invest; 2016; 81(6):529-536. PubMed ID: 27160772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.